Wednesday, October 1, 2014
Inquirer Daily News

Endo Pharmaceuticals halts work on implant

The Chadds Ford company won't proceed with an experimental implant to treat a condition caused by the body's overproduction of growth hormone.

Endo Pharmaceuticals halts work on implant

Endo Pharmaceuticals Holdings has halted development of an implant to treat the abnormal growth of hands and feet that caused by the body's overproduction of growth hormone. The Chadds Ford company had been asked by the Food and Drug Administration in February for more animal studies on the implant, Reuters reports.

Worth reading is a Wall Street Journal update on online-only annual shareholder meetings. Nutrisystem is one of the 25 companies nationwide that have held their annual meeting online since December 2009. But, as Joann Lublin reports, the format's not exactly catching on in a big way.

In other local business news, Kenexa acquired Batrus Hollweg, a human resources consulting firm based in Dallas. Kenexa, a Wayne-based tech firm focused on the HR world, did not disclose what it paid, but is picking up an organization that has strong sales into the hospitality sector.

Mike Armstrong Inquirer Columnist
About this blog
Mike Armstrong blogs about Philadelphia corporations and business-related topics. Contact him at 215-854-2980. Reach Mike at marmstrong@phillynews.com.

Mike Armstrong Inquirer Columnist
Business Videos:
Also on Philly.com:
Stay Connected